Doxorubicin liposomal - Taiwan Liposome Company

Drug Profile

Doxorubicin liposomal - Taiwan Liposome Company

Alternative Names: Lipo-Dox; TLC 177

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiwan Liposome Company
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Kaposi's sarcoma; Ovarian cancer

Most Recent Events

  • 19 May 2017 Preregistration for Breast cancer in European Union (IV)
  • 19 May 2017 Preregistration for Ovarian cancer in European Union (IV)
  • 29 Sep 2016 TLC regains the distribution right for doxorubicin liposomal from Teva for USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top